Showing 1 - 9 results of 9 for search 'Raoul Tibes', query time: 0.04s Refine Results
  1. 1
    RNA INTERFERENCE (RNAI): AN EFFECTIVE WAY TO DEVELOP RATIONAL COMBINATION THERAPIES WITH HYPOMETHYLATING AGENTS IN ACUTE LEUKAEMIAS AND MYELODYSPLASTIC SYNDROME

    RNA INTERFERENCE (RNAI): AN EFFECTIVE WAY TO DEVELOP RATIONAL COMBINATION THERAPIES WITH HYPOMETHYLATING AGENTS IN ACUTE LEUKAEMIAS AND MYELODYSPLASTIC SYNDROME by Raoul Tibes

    Published 2013-08-01
    Get full text
    Article
  2. 2
    Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome

    Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome by Glen J. Weiss, Raoul Tibes, Lisa Blaydorn, Gayle Jameson, Molly Downhour, Erica White, Ivor Caro, Daniel D. Von Hoff

    Published 2011-12-01
    Get full text
    Article
  3. 3
    Triazolo[4,5-d]pyrimidines as Validated General Control Nonderepressible 2 (GCN2) Protein Kinase Inhibitors Reduce Growth of Leukemia Cells

    Triazolo[4,5-d]pyrimidines as Validated General Control Nonderepressible 2 (GCN2) Protein Kinase Inhibitors Reduce Growth of Leukemia Cells by Lea Lough, Dan Sherman, Manuel Becerra-Flores, Deepika Vasudevan, Olga Lavinda, Eric Ni, Hong Wang, Hyung Don Ryoo, Raoul Tibes, Timothy Cardozo

    Published 2018-01-01
    Get full text
    Article
  4. 4
    Corrigendum to “Triazolo[4,5-d]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells” [Comput. Struct. Biotechnol. J. 16 (2018) 350–360]

    Corrigendum to “Triazolo[4,5-d]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells” [Comput. Struct. Biotec... by Lea Lough, Dan Sherman, Manuel Becerra-Flores, Deepika Vasudevan, Olga Lavinda, Eric Ni, Hong Wang, Hyung Don Ryoo, Raoul Tibes, Timothy Cardozo

    Published 2020-01-01
    Get full text
    Article
  5. 5
    The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials

    The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials by Mitesh J. Borad, Kelly K. Curtis, Hani M. Babiker, Martin Benjamin, Raoul Tibes, Ramesh K. Ramanathan, Karen Wright, Amylou C. Dueck, Gayle Jameson, Daniel D. Von Hoff

    Published 2012-01-01
    Get full text
    Article
  6. 6
    P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY

    P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY by Pinkal Desai, Sagar Lonial, Amanda Cashen, Manali Kamdar, James S. Blachly, Ian W. Flinn, Susan O’brien, Jacqueline Garcia, Neha Korde, Javid Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma, Damilola Olabode, Hong Chen, Firasath Ali Syed, Mary Liu, Jamal Saeh, Raoul Tibes, Marcio Andrade, Tapan Kadia

    Published 2023-08-01
    Get full text
    Article
  7. 7
    P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

    P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL by Giovanni Marconi, Shukaib Arslan, Shaun Fleming, Antonio Curti, James S Blachly, Giovanni Martinelli, Matteo Giovanni Della Porta, Ashish Bajel, Tim Sauer, Martina Crysandt, Arnaud Pigneux, Marina Konopleva, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Emily Rowe, Patricia Cheung, Ekaterina Jahn, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Nitin Jain

    Published 2023-08-01
    Get full text
    Article
  8. 8
    Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia

    Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia by Andoni Garitano-Trojaola, Ana Sancho, Ralph Götz, Patrick Eiring, Susanne Walz, Hardikkumar Jetani, Jesus Gil-Pulido, Matteo Claudio Da Via, Eva Teufel, Nadine Rhodes, Larissa Haertle, Estibaliz Arellano-Viera, Raoul Tibes, Andreas Rosenwald, Leo Rasche, Michael Hudecek, Markus Sauer, Jürgen Groll, Hermann Einsele, Sabrina Kraus, Martin K. Kortüm

    Published 2021-06-01
    Get full text
    Article
  9. 9
    The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes

    The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes by Tamara K. Moyo, Jason H. Mendler, Raphael Itzykson, Ashwin Kishtagari, Eric Solary, Adam C. Seegmiller, Aaron T. Gerds, Gregory D. Ayers, Amy E. Dezern, Aziz Nazha, Peter Valent, Arjan A. van de Loosdrecht, Francesco Onida, Lisa Pleyer, Blanca Xicoy Cirici, Raoul Tibes, Klaus Geissler, Rami S. Komrokji, Jing Zhang, Ulrich Germing, David P. Steensma, Daniel H. Wiseman, Michael Pfeilstöecker, Chiara Elena, Nicholas C. P. Cross, Jean-Jacques Kiladjian, Michael Luebbert, Ruben A. Mesa, Guillermo Montalban-Bravo, Guillermo F. Sanz, Uwe Platzbecker, Mrinal M. Patnaik, Eric Padron, Valeria Santini, Pierre Fenaux, Michael R. Savona, On Behalf of the MDS/MPN International Working Group

    Published 2022-09-01
    Get full text
    Article

Search Tools: